Table 3.

Pretreatment Characteristics of 256 ALL Patients by Cytogenetic Risk Group

Characteristics Risk GroupTotal
Unfavorable Miscellaneous Normal
No. of patients 100 77 79 256
Age (yr)
 Median (range) 43 (16-78)3-150 27 (16-80)30 (16-78) 33 (16-80)
 <3028 (28%) 43 (56%) 38 (48%)109 (43%)
 30-59 49 (49%)26 (34%) 30 (38%) 105 (41%)
 ≥60 23 (23%) 8 (10%)11 (14%) 42 (16%)
Sex
 Males52 (52%)3-151 48 (62%) 55 (70%)155 (61%)
 Females 48 (48%)29 (38%) 24 (30%) 101 (39%)
Mediastinal mass (n = 252): present 1 (1%)3-152 14 (18%) 8 (10%) 23 (9%)
Splenomegaly (n = 249): present 16 (19%)35 (45%)3-151 22 (29%) 75 (30%)
Lymphadenopathy (n = 247): present 29 (30%)47 (63%)3-152 29 (38%) 105 (43%)
Median WBC count (×103; n = 255) 33.03-150 18.89.9 19.3
 Range (1.0-392)(0.7-326) (0.7-411)(0.7-411)
 ≥30.053 (53%) 27 (36%) 20 (25%)100 (39%)
Median platelet count (×103; n = 255) 56.03-150 67.0 82.0 61.0
 Range  (12-342)   (4-400) (16-763)(4-763)
Immunophenotype by uniparameter flow cytometry (n = 105)
 B 20 (57%)3-150 16 (44%) 9 (26%) 45 (43%)
 BMy 9 (26%) 3 (8%)10 (29%) 22 (21%)
 T 2 (6%)12 (33%) 10 (29%) 24 (23%)
 TMy 0 3 (8%) 3 (9%)6 (6%)
 Other 4 (11%)2 (6%) 2 (6%) 8 (8%)
Immunophenotype by multiparameter flow cytometry (n = 116)
 B 34 (71%)3-150 20 (57%)15 (45%) 69 (59%)
 BMy12 (25%) 5 (14%) 6 (18%)23 (20%)
 T 0 4 (11%)10 (30%) 14 (12%)
 TMy 03 (9%) 1 (3%) 4 (3%)
 Other2 (4%) 3 (9%) 1 (3%)6 (5%)
Treatment protocols
 8011, 8411, 851322 (22%) 20 (26%) 25 (32%)67 (26%)
 8811, 9111, 9311 78 (78%)57 (74%) 54 (68%)189 (74%)
  • Presence of central nervous system disease, hepatomegaly, and the French-American-British classification did not differ between the groups. P values represent difference from the normal karyotype group (for immunophenotype the comparison is for B-lineagev T-lineage).

  • Abbreviations: ND, not done; NE, not evaluable.

  • F3-150 P < .005.

  • F3-151 .01 < P < .05.

  • F3-152 .005 < P < .01.